Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 133 Impact on Gastric Emptying in Overweight or Obesity
NCT07429032Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maridebart cafraglutide in obesity, sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration for Acetaminophen at Day 86, Time to Cmax for Acetaminophen at Day 86 and 3 more. Started Apr 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07429032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429032.